Literature DB >> 30541380

Observatoire Français de la Sclérose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France.

Sandra Vukusic1, Romain Casey1, Fabien Rollot1, Bruno Brochet2, Jean Pelletier3, David-Axel Laplaud4, Jérôme De Sèze5, François Cotton6, Thibault Moreau7, Bruno Stankoff8, Bertrand Fontaine9, Francis Guillemin10, Marc Debouverie11, Michel Clanet12.   

Abstract

The care of multiple sclerosis (MS) in France is based on two complementary interlinked networks: MS expert centers in university hospitals and regional networks of neurologists. The routine use of European database for multiple sclerosis (EDMUS) in all those centers has paved the way for the constitution of a national registry, designated as Observatoire Français de la Sclérose En Plaques (OFSEP). It promotes a prospective, standardized, high-quality, and multimodal collection of data. On June 2018, there were 68.097 files, with 71.1% females, representing 761,185 person-years. This huge database is open to the scientific community and might contribute exploring unresolved issues and unmet needs in MS.

Entities:  

Keywords:  Multiple sclerosis; database; epidemiology; quality; registry

Year:  2018        PMID： 30541380     DOI： 10.1177/1352458518815602

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


  11 in total

1.  Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.

Authors:  Sandra Vukusic; Fabien Rollot; Romain Casey; Julie Pique; Romain Marignier; Guillaume Mathey; Gilles Edan; David Brassat; Aurélie Ruet; Jérôme De Sèze; Elisabeth Maillart; Hélène Zéphir; Pierre Labauge; Nathalie Derache; Christine Lebrun-Frenay; Thibault Moreau; Sandrine Wiertlewski; Eric Berger; Xavier Moisset; Audrey Rico-Lamy; Bruno Stankoff; Caroline Bensa; Eric Thouvenot; Olivier Heinzlef; Abdullatif Al-Khedr; Bertrand Bourre; Mathieu Vaillant; Philippe Cabre; Alexis Montcuquet; Abir Wahab; Jean-Philippe Camdessanché; Ayman Tourbah; Anne-Marie Guennoc; Karolina Hankiewicz; Ivania Patry; Chantal Nifle; Nicolas Maubeuge; Céline Labeyrie; Patrick Vermersch; David-Axel Laplaud
Journal:  JAMA Neurol       Date:  2020-01-01       Impact factor: 18.302

2.  NARCOMS and Other Registries in Multiple Sclerosis: Issues and Insights.

Authors:  Ruth Ann Marrie; Gary R Cutter; Robert J Fox; Timothy Vollmer; Tuula Tyry; Amber Salter
Journal:  Int J MS Care       Date:  2021-12-29

3.  Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal.

Authors:  Fabien Rollot; Justine Couturier; Romain Casey; Sandrine Wiertlewski; Marc Debouverie; Jean Pelletier; Jérôme De Sèze; Pierre Labauge; Aurélie Ruet; Eric Thouvenot; Jonathan Ciron; Eric Berger; Olivier Gout; Pierre Clavelou; Bruno Stankoff; Olivier Casez; Bertrand Bourre; Hélène Zephir; Thibault Moreau; Christine Lebrun-Frenay; Elisabeth Maillart; Gilles Edan; Jean-Philippe Neau; Alexis Montcuquet; Philippe Cabre; Jean-Philippe Camdessanché; Gilles Defer; Haifa Ben Nasr; Aude Maurousset; Karolina Hankiewicz; Corinne Pottier; Emmanuelle Leray; Sandra Vukusic; David-Axel Laplaud
Journal:  Neurotherapeutics       Date:  2022-02-25       Impact factor: 6.088

4.  Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.

Authors:  M Lefort; S Sharmin; J B Andersen; M Magyari; T Kalincik; E Leray; S Vukusic; R Casey; M Debouverie; G Edan; J Ciron; A Ruet; J De Sèze; E Maillart; H Zephir; P Labauge; G Defer; C Lebrun-Frenay; T Moreau; E Berger; P Clavelou; J Pelletier; B Stankoff; O Gout; E Thouvenot; O Heinzlef; A Al-Khedr; B Bourre; O Casez; P Cabre; A Montcuquet; A Wahab; J P Camdessanché; A Maurousset; H Ben Nasr; K Hankiewicz; C Pottier; N Maubeuge; D Dimitri-Boulos; C Nifle; D A Laplaud; D Horakova; E K Havrdova; R Alroughani; G Izquierdo; S Eichau; S Ozakbas; F Patti; M Onofrj; A Lugaresi; M Terzi; P Grammond; F Grand'Maison; B Yamout; A Prat; M Girard; P Duquette; C Boz; M Trojano; P McCombe; M Slee; J Lechner-Scott; R Turkoglu; P Sola; D Ferraro; F Granella; V Shaygannejad; J Prevost; D Maimone; O Skibina; K Buzzard; A Van der Walt; R Karabudak; B Van Wijmeersch; T Csepany; D Spitaleri; S Vucic; N Koch-Henriksen; F Sellebjerg; P S Soerensen; C C Hilt Christensen; P V Rasmussen; M B Jensen; J L Frederiksen; S Bramow; H K Mathiesen; K I Schreiber; H Butzkueven
Journal:  BMC Med Res Methodol       Date:  2022-05-30       Impact factor: 4.612

5.  Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome.

Authors:  Christine Lebrun-Frénay; Fabien Rollot; Lydiane Mondot; Helene Zephir; Celine Louapre; Emmanuelle Le Page; Françoise Durand-Dubief; Pierre Labauge; Caroline Bensa; Eric Thouvenot; David Laplaud; Jerome de Seze; Jonathan Ciron; Bertrand Bourre; Philippe Cabre; Olivier Casez; Aurélie Ruet; Guillaume Mathey; Eric Berger; Thibault Moreau; Abdulatif Al Khedr; Nathalie Derache; Pierre Clavelou; Anne-Marie Guennoc; Alain Créange; Jean-Philippe Neau; Ayman Tourbah; Jean-Philippe Camdessanché; Adil Maarouf; Celine Callier; Patrick Vermersch; Orhun Kantarci; Aksel Siva; Christina Azevedo; Naila Makhani; Mikael Cohen; Daniel Pelletier; Darin Okuda; Sandra Vukusic
Journal:  JAMA Netw Open       Date:  2021-10-01

6.  Effectiveness of Anti-Cluster of Differentiation 20 as a Disease-Modifying Therapy in Multiple Sclerosis Across Its Different Phenotypes at the University Hospital of Caen.

Authors:  Moayyad S Bauthman
Journal:  Cureus       Date:  2022-02-11

7.  Overall and patient-level comparative effectiveness of dimethyl fumarate and fingolimod: A precision medicine application to the Observatoire Français de la Sclérose en Plaques registry.

Authors:  Gabrielle Simoneau; Xiaotong Jiang; Fabien Rollot; Lu Tian; Massimiliano Copetti; Matthieu Guéry; Marta Ruiz; Sandra Vukusic; Carl de Moor; Fabio Pellegrini
Journal:  Mult Scler J Exp Transl Clin       Date:  2022-08-04

8.  Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis: A multicenter cross-sectional study.

Authors:  Álvaro Cobo-Calvo; Hyacintha d'Indy; Anne Ruiz; Nicolas Collongues; Laurent Kremer; Françoise Durand-Dubief; Fabien Rollot; Romain Casey; Sandra Vukusic; Jérôme De Seze; Romain Marignier
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-12-13

9.  Use of healthcare services by patients with multiple sclerosis in France over 2010-2015: a nationwide population-based study using health administrative data.

Authors:  J Roux; A Guilleux; M Lefort; E Leray
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-12-18

10.  Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals.

Authors:  Sylvain Lehmann; Julien Dumurgier; Xavier Ayrignac; Cecilia Marelli; Daniel Alcolea; Juan Fortea Ormaechea; Eric Thouvenot; Constance Delaby; Christophe Hirtz; Jérôme Vialaret; Nelly Ginestet; Elodie Bouaziz-Amar; Jean-Louis Laplanche; Pierre Labauge; Claire Paquet; Alberto Lleo; Audrey Gabelle
Journal:  Alzheimers Res Ther       Date:  2020-10-02       Impact factor: 6.982
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.